Table 2. The most frequent CGH alterations in relation to the total number of alterations detected in the 39 MFH.

	No. of	Gain involving chromosomal regions
Case no	changes	20q	17p	7q21	1p31	1q23–24	17q	9cen-q22	16p	Other gains	Other losses
1	0
2	0
3	1	20q
4	1		17p
5	1		17p
6	1									12p
7	1									4p
8	1			7q
9	1										4q
10	1										1q41-qter
11	1										20p
12	1									12q14–15
13	1				1p31–q24	1p31–q24
14	2	20q								10p
15	2		17p				17q			Xp
16	2							9cen-q22		Xq,
17	2			7cen-q31					16p
18	2									1p32–34	9p13-pter
19	2	20q					17q
20	3		17p					9q		15q24-qter
21	3										11, 14q, 16q
22	4	20q	17p							12q12–15	9p
23	4	20q							16p	7p	X
24	5									11cen-q13	4, 5q14–q23, 13q14–32 , 6q14–q16
25	5	20q	17p		1p31-pter	1q11–24	17q			5p,12q23-qter, 18p
26	5		17p		1p31-pter		17q		16p	9q34-qter, 11cen-q13
27	6	20q					17q	9q	16p	6p	13q
28	7		17p					9q		8q21.1–q22, 12q11–15,	8p21-pter, 20p
29	7		17p	7cen-q21			17q		16p	2p22-pter, 6p, 7p, 9q33-qter	13q12–31
30	7		17p			1q23–32	17q		16	6p24–26, 6q24-26, 12q13–21	9p
31	8		17p	7q11.1-21					16p	10p, 11cen-q13, 13q14-qter, Xpter-q21	8q22-qter
32	8		17p		1p31-pter		17q	9q	16p	6q22–24, 13q31-qter, 18p	8,
33	9	20q	17p	7q			17q	9q		6p21.3-pter, 6q24-qter, 7p, 15q, 18p	3q
34	9	20q					17q			4p15.3-pter, 5p, 10p, 11cen-q13	3q, 6q11–21, 9p21-pter
35	11	20q	17p	7q	1p31-pter		17q		16p	7p, 11p14-q13, 18p	4, 6q, 10, 13q14-qter
36	11	20q		7q21–32	1cen-p31			9cen-q22	16p	4q13–24, 11cen-q13	1q21-qter, 9p, 13q, 11q22-qter
37	12	20q	17p	7cen-q21	1p31-pter	1q23–25		9q	16p	7p, 8p11.2–12, 11cen-q14, Xp, 13q22-qter, 19q12–13.2
38	15	20q	17p		1p21-pter	1cen-q32	17q		16p	2q12.2–21, 6p21.1–21.3, 6q24-qter8p, 15q, 18, Xp	4q21-qter, 6q12–22, 11q21-qter
39	16	20q	17p	7cen-q32	1p	1cen-q31		9q		2p13–q21, 3q, 5p, 6, 8q24.1-qter,12q, 21q, Xp	2q33-qter, 3p23-pter, 10q23-qter

Bold letter represents high-level amplification.